Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus

J Pediatr. 2008 Apr;152(4):582-4. doi: 10.1016/j.jpeds.2007.12.020.

Abstract

5 of 6 children infected with human immunodeficiency virus (HIV) receiving Tenofovir disoproxil fumarate (TDF) experienced absolute decreases in bone mineral density (BMD). 2 pre-pubertal subjects experienced >6% BMD decreases. 1 subject was the smallest child and experienced a 27% decrease, necessitating withdrawal of TDF. Subsequently, her BMD recovered. Monitoring of children infected with HIV who require treatment with TDF is warranted.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Absorptiometry, Photon
  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Adenine / therapeutic use
  • Adolescent
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Bone Density / drug effects*
  • Child
  • Female
  • HIV
  • HIV Infections / drug therapy*
  • HIV Infections / physiopathology
  • Humans
  • Male
  • Organophosphonates / pharmacology*
  • Organophosphonates / therapeutic use
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Tenofovir
  • Adenine